Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse

 
• By Mandy Jackson

Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.

Linking entities, Network simulation, social media, Communications Network, The connection between the two networks. in paper linked together by cotton with a black yarn - Image
The data support an expanded patient base for Nuplazid

More from Clinical Trials

More from R&D